SPN monoclonal antibody (11)
Product Specifications
Background
Fully humanized monoclonal antibody paired with human monoclonal antibody It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
CAS Number
9007-83-4
Structure Composition
1mg/ml in PBS with 0.02% sodium azide, pH7.2
Product Name Alternative
Nucleocapsid phosphoprotein; Severe acute respiratory syndrome coronavirus 2; SARS-CoV-2; HCoV-19; SARS2; 2019-nCoV; COVID-19; COVID-19 virus; Human coronavirus 2019
Swiss Prot
QHD43423.2
Reactivity
COVID-19
Immunogen
Fully humanized monoclonal antibody paired with human monoclonal antibody, corresponding to COV-19 SPN.
Applications
ELISA WB
Dilution
ELISA:1:40000 WB: 1:2000~3000
Purity
The antibody was purified from 293f recombinant protein and the purity is > 95% (by SDS-PAGE) .
Storage Conditions
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Notes
For research use only, not for use in diagnostic procedure.
Specificity
SPN mAb detects endogenous levels of SPN protein.
Host or Source
Human
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
170984 50 µg
MST1R (RON, C-met-related Tyrosine Kinase, CD136, CDw136, CD136 Antigen, Friend virus susceptibility 2, Fv2, MSP Receptor, p185-Ron, PTK8 Protein Tyrosine Kinase 8, RON, Soluble RON variant 3, Soluble RON variant 1, MST1R Variant RON30, Oncogene RON, PTK8, MST1R Variant RON62, Protein-Tyrosine Kinase 8, RON Variant E2E3, Soluble RON Variant 2, Soluble RON Variant 4)
Ask
View Details 